Tango Therapeutics (TNGX) EBT (2020 - 2026)

Tango Therapeutics' EBT history runs 7 years deep, the most recent figure standing at -$45.5 million for Q1 2026.

• On a quarterly basis, EBT fell 14.23% year-over-year to -$45.5 million in Q1 2026; TTM through Mar 2026 was -$107.3 million, a 18.78% increase from a year earlier, with the FY2025 full-year figure at -$101.6 million, up 21.91% from the prior year.
• EBT eased to -$45.5 million in Q1 2026 per TNGX's latest filing, from -$38.8 million in the prior quarter.
• Across five years, EBT topped out at $15.9 million in Q3 2025 and bottomed at -$45.5 million in Q1 2026.
• The 5-year median for EBT is -$29.0 million (2022), against an average of -$28.6 million.
• Across the five-year window, EBT tumbled 450.62% in 2022 and jumped 154.53% in 2025, its largest moves.
• Year by year, EBT stood at -$29.0 million in 2022, then retreated by 5.88% to -$30.7 million in 2023, then declined by 22.48% to -$37.6 million in 2024, then fell by 3.14% to -$38.8 million in 2025, then declined by 17.29% to -$45.5 million in 2026.
• Per Business Quant, the three latest TNGX EBT figures stand at -$45.5 million (Q1 2026), -$38.8 million (Q4 2025), and $15.9 million (Q3 2025).